SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

BioInvent International AB ($BOVNF) announced an update on their ongoing clinical study. Study Overview: BioInvent International AB, in ...

Lytix Biopharma AS ($DE:6BG) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 2 Study of ...

Early MRI predicts pathologic complete response and long-term outcomes in TNBC patients receiving pembrolizumab.

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

SYDNEY, Dec. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today announced new data from two presentations at the 2025 San Antonio Breast Cancer ...

FDA approves pembrolizumab and enfortumab vedotin for neoadjuvant and adjuvant treatment of cisplatin-ineligible muscle-invasive bladder cancer.